HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BAO PHARMA-B

14.470

-0.430-2.89%

Volume:143.30K

Turnover:2.07M

Market Cap:4.67B

PE:-9.11

High:14.900

Open:14.900

Low:14.330

Close:14.900

52wk High:206.000

52wk Low:14.330

Shares:323.00M

HK Float Shares:152.00M

Volume Ratio:0.92

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.589

ROE:-31.30%

ROA:-10.46%

PB:2.76

PE(LYR):-9.11

PS:234.75

Loading ...

Overview Company News Filings

BAO PHARMA-B's Investigational New Drug Application for BJ044 (Recombinant Ulinastatin) Receives NMPA Approval

Shanghai Bao Pharmaceuticals Co - Nmpa Approves Ind Application for Bj044 Injection, Permitting Clinical Trials

THOMSON REUTERS

BAO PHARMA-B Shares Surge in Morning Session Following NMPA Acceptance of New Drug Application

Bubble Burst Leaves Stock in Tatters: This Company's Shares Suffer a 'Foot-Ankle Chop'

BAO PHARMA-B Surges Over 4% on Successful Phase II Trial for Novel IgG Degrading Enzyme

Bao Pharma Secures U.S. FDA IND Clearance to Begin Clinical Trials of Subcutaneous Ceftriaxone Candidate BJ007

Bulletin Express

BAO PHARMA-B Receives FDA Clearance for Clinical Trial of Subcutaneous Antibiotic Candidate BJ007

Shanghai Bao Pharma says US FDA clears IND for BJ007 subcutaneous infusion trial

Shanghai Bao Pharmaceuticals Co - U.S. FDA Approves Ind for Subcutaneous Infusion of Bj007 for Injection on May 27, 2026

THOMSON REUTERS

Movement Alert｜Bao Pharmaceuticals-B Falls 5.19% in Regular Trading, Continued Low-Level Consolidation After Flash Crash Compounded by Biotech Sector Weakness

BAO PHARMA-B's Groundbreaking Low-Immunogenic IgG Degrading Enzyme Ricefidase Reports Positive Phase II Results for Anti-GBM Disease

Movement Alert｜Bao Pharmaceuticals-B Rises 5.59% in Regular Trading, Core Pipeline KJ103 NDA Accepted by NMPA with Priority Review

Bao Pharmaceuticals' Application for Desensitization Therapy Drug Accepted in China

MT Newswires Live

BRIEF-Shanghai Bao Pharmaceuticals Says NMPA Accepts NDA For KJL03 For Injection

BAO PHARMA-B gains NMPA priority review for first-in-class IgG-degrading enzyme KJ103 in kidney transplant desensitization

Bulletin Express

Baoji Pharmaceutical-B Receives NMPA Acceptance for New Drug Application of Injectable KJ103

Shanghai Bao Pharma says China NMPA accepts KJ103 injection NDA for kidney transplant desensitization therapy

Shanghai Bao Pharmaceuticals Co - Nmpa Accepts Nda for Kj103 for Injection on June 4, 2026

THOMSON REUTERS

Movement Alert｜Baoji Pharma-B Rises 13.37% in Regular Trading, Oversold Rebound After Hitting 52-Week Low Amid Multiple Positive Catalysts

Movement Alert｜BaoPharma-B Falls 5.3% in Regular Trading, Biotech Sector Systematic Weakness Extends Selling Pressure

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/02659/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"BAO PHARMA-B","latestPrice":14.47,"timestamp":1789095618733,"preClose":14.9,"halted":0,"volume":143300,"delay":0,"changeRate":-0.028859060402684544,"floatShares":152000000,"shares":323000000,"eps":-1.58896305125149,"marketStatus":"Trading","change":-0.43,"latestTime":"09-11 11:01:10","open":14.9,"high":14.9,"low":14.33,"amount":2073675,"amplitude":0.038255,"askPrice":14.5,"askSize":4300,"bidPrice":14.47,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-1.3825380572109653,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1789099200000},"marketStatusCode":2,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":14.9,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.924114,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":152000000,"roa":"-10.46%","roe":"-31.30%","lyrEps":-1.58897,"volumeRatio":0.924114,"shares":323000000,"dividePrice":0,"high":14.9,"amplitude":0.038255,"preClose":14.9,"low":14.33,"week52Low":14.33,"pbRate":"2.76","psRate":"234.75","week52High":206,"institutionHeld":0,"latestPrice":14.47,"committee":-0.791667,"eps":-1.5889701246765466,"divideRate":0,"volume":143300,"delay":0,"ttmEps":-1.3825442117148903,"open":14.9,"prevYearClose":77.55,"prevWeekClose":16.06,"prevMonthClose":16.44,"prevQuarterClose":18,"fiveDayClose":16.06,"twentyDayClose":16.9,"sixtyDayClose":18.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-26","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1779984000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2026-09-10","current":-10.401323,"percent":0.972678,"low":-150.791275,"twenty":-74.869258,"median":-34.777261,"eighty":-12.694977,"high":-11.128507,"avg":-45.67798,"sd":35.743734,"marketCap":4855705348},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-19","current":-56.628418,"twenty":-56.115318,"median":-53.146224,"eighty":-50.330094,"marketCap":23796646945},{"date":"2025-12-24","current":-60.667186,"twenty":-57.368285,"median":-54.841733,"eighty":-51.357726,"marketCap":25573245929},{"date":"2026-01-02","current":-53.689307,"twenty":-58.867149,"median":-56.13619,"eighty":-51.993778,"marketCap":22720908110},{"date":"2026-01-09","current":-60.663453,"twenty":-59.744205,"median":-56.240552,"eighty":-53.146224,"marketCap":25736236661},{"date":"2026-01-16","current":-77.814349,"twenty":-61.547088,"median":-57.565784,"eighty":-53.651638,"marketCap":33119716844},{"date":"2026-01-23","current":-76.125836,"twenty":-72.759479,"median":-58.867149,"eighty":-53.689307,"marketCap":32369959474},{"date":"2026-01-30","current":-79.366151,"twenty":-76.125836,"median":-60.665319,"eighty":-55.0155,"marketCap":33902072360},{"date":"2026-02-06","current":-84.493791,"twenty":-76.125836,"median":-61.547088,"eighty":-55.626475,"marketCap":36183942615},{"date":"2026-02-13","current":-126.016863,"twenty":-78.017279,"median":-67.830536,"eighty":-56.031828,"marketCap":54275913922},{"date":"2026-02-20","current":-138.174242,"twenty":-79.686668,"median":-71.167377,"eighty":-56.115318,"marketCap":59426421069},{"date":"2026-02-27","current":-116.132786,"twenty":-104.714701,"median":-73.426035,"eighty":-56.395698,"marketCap":50494528928},{"date":"2026-03-06","current":-76.640212,"twenty":-111.983375,"median":-74.892856,"eighty":-56.998352,"marketCap":33054520551},{"date":"2026-03-13","current":-75.987902,"twenty":-110.582832,"median":-75.36732,"eighty":-57.563278,"marketCap":32924127965},{"date":"2026-03-20","current":-70.725897,"twenty":-109.509649,"median":-74.892856,"eighty":-57.733099,"marketCap":30528164197},{"date":"2026-03-27","current":-65.400661,"twenty":-104.714701,"median":-74.674242,"eighty":-58.326024,"marketCap":29273135557},{"date":"2026-04-02","current":-74.510382,"twenty":-96.653813,"median":-73.605533,"eighty":-59.04256,"marketCap":33510894602},{"date":"2026-04-10","current":-71.602503,"twenty":-91.308972,"median":-74.057958,"eighty":-59.568794,"marketCap":32451454840},{"date":"2026-04-17","current":-64.454748,"twenty":-86.399914,"median":-73.087213,"eighty":-60.479603,"marketCap":29224238337},{"date":"2026-04-24","current":-55.967849,"twenty":-84.718643,"median":-71.1642,"eighty":-60.173931,"marketCap":25377657050},{"date":"2026-04-30","current":-18.543355,"twenty":-83.426575,"median":-70.300184,"eighty":-58.506399,"marketCap":8410321797},{"date":"2026-05-08","current":-19.625214,"twenty":-81.092081,"median":-69.74185,"eighty":-56.760202,"marketCap":8931892141},{"date":"2026-05-15","current":-17.930681,"twenty":-79.944236,"median":-68.961959,"eighty":-55.831299,"marketCap":8182134771},{"date":"2026-05-22","current":-17.55647,"twenty":-79.579829,"median":-66.237091,"eighty":-53.674239,"marketCap":7993065521},{"date":"2026-05-29","current":-17.509903,"twenty":-78.962132,"median":-66.085797,"eighty":-51.516739,"marketCap":7999585151},{"date":"2026-06-05","current":-15.389804,"twenty":-78.220574,"median":-65.202887,"eighty":-19.743808,"marketCap":7041199644},{"date":"2026-06-12","current":-13.774642,"twenty":-77.936107,"median":-64.592987,"eighty":-19.178821,"marketCap":6297961903},{"date":"2026-06-18","current":-12.785133,"twenty":-77.726882,"median":-64.454748,"eighty":-18.7468,"marketCap":5857886926},{"date":"2026-06-26","current":-11.736313,"twenty":-77.358698,"median":-62.675612,"eighty":-18.25553,"marketCap":5352615655},{"date":"2026-07-03","current":-13.348826,"twenty":-77.285436,"median":-61.290684,"eighty":-17.828553,"marketCap":6092593580},{"date":"2026-07-10","current":-14.187594,"twenty":-77.122448,"median":-60.663453,"eighty":-17.509903,"marketCap":6467472265},{"date":"2026-07-17","current":-12.348746,"twenty":-76.777398,"median":-59.36056,"eighty":-15.389804,"marketCap":5649258788},{"date":"2026-07-24","current":-12.28898,"twenty":-76.640212,"median":-57.965274,"eighty":-14.102609,"marketCap":5623180271},{"date":"2026-07-31","current":-12.265678,"twenty":-76.228711,"median":-57.553252,"eighty":-13.925373,"marketCap":5623180271},{"date":"2026-08-07","current":-12.759971,"twenty":-76.015489,"median":-56.434485,"eighty":-13.758151,"marketCap":5861146740},{"date":"2026-08-14","current":-11.978357,"twenty":-75.491436,"median":-55.967849,"eighty":-13.50755,"marketCap":5509086758},{"date":"2026-08-21","current":-11.379099,"twenty":-75.31975,"median":-54.455852,"eighty":-13.139203,"marketCap":5245041771},{"date":"2026-08-28","current":-11.185615,"twenty":-75.047246,"median":-53.651638,"eighty":-12.841314,"marketCap":5157026776},{"date":"2026-09-04","current":-12.259564,"twenty":-74.97059,"median":-51.596245,"eighty":-12.752538,"marketCap":5233733415},{"date":"2026-09-10","current":-11.358738,"twenty":-74.869258,"median":-34.777261,"eighty":-12.694977,"marketCap":4855705348}],"updateTime":1789095044922},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1102812606","title":"BAO PHARMA-B's Investigational New Drug Application for BJ044 (Recombinant Ulinastatin) Receives NMPA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1102812606","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102812606?lang=en_us&edition=fundamental","pubTime":"2026-06-30 08:32","pubTimestamp":1782779549,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (ASX: 02659) has announced that on June 29, 2026, the Investigational New Drug (IND) application for its self-developed, globally leading BJ044 injection (recombinant ulinastatin, BJ044)...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647300942","title":"Shanghai Bao Pharmaceuticals Co - Nmpa Approves Ind Application for Bj044 Injection, Permitting Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2647300942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647300942?lang=en_us&edition=fundamental","pubTime":"2026-06-30 06:36","pubTimestamp":1782772602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN43111G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197374184","title":"BAO PHARMA-B Shares Surge in Morning Session Following NMPA Acceptance of New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1197374184","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197374184?lang=en_us&edition=fundamental","pubTime":"2026-06-29 11:10","pubTimestamp":1782702635,"startTime":"0","endTime":"0","summary":"Shares of BAO PHARMA-B (ASX: 02659) rose sharply during the morning trading session. At the time of reporting, the stock was up 9.01% to HK$17.9, with a turnover of HK$19.52 million.The upward...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","02659","VXUS","IPOS","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150861943","title":"Bubble Burst Leaves Stock in Tatters: This Company's Shares Suffer a 'Foot-Ankle Chop'","url":"https://stock-news.laohu8.com/highlight/detail?id=1150861943","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150861943?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:17","pubTimestamp":1781615869,"startTime":"0","endTime":"0","summary":"Shares of BAO PHARMA-B (HKEX: 2659), which had just completed six months of listing on the Hong Kong Stock Exchange, fell another 4.21% today (16th), closing at HK$18.41 to set a new historical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105703662","title":"BAO PHARMA-B Surges Over 4% on Successful Phase II Trial for Novel IgG Degrading Enzyme","url":"https://stock-news.laohu8.com/highlight/detail?id=1105703662","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105703662?lang=en_us&edition=fundamental","pubTime":"2026-06-11 10:06","pubTimestamp":1781143587,"startTime":"0","endTime":"0","summary":"Shares of BAO PHARMA-B (ASX: 02659) have surged more than 4%. At the time of writing, the stock is up 4.03% to HKD 19.88, with a turnover of HKD 7.918 million.The recent price movement follows the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4588","02659","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127315645","title":"Bao Pharma Secures U.S. FDA IND Clearance to Begin Clinical Trials of Subcutaneous Ceftriaxone Candidate BJ007","url":"https://stock-news.laohu8.com/highlight/detail?id=1127315645","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127315645?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:45","pubTimestamp":1781088350,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (“Bao Pharma”) announced that the U.S. Food and Drug Administration granted Investigational New Drug (IND) clearance on 27 May 2026 for BJ007, a subcutaneous...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193425517","title":"BAO PHARMA-B Receives FDA Clearance for Clinical Trial of Subcutaneous Antibiotic Candidate BJ007","url":"https://stock-news.laohu8.com/highlight/detail?id=1193425517","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193425517?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:32","pubTimestamp":1781087562,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (ASX: 02659) has announced that its Investigational New Drug (IND) application for BJ007, a subcutaneous formulation of ceftriaxone sodium, has been approved by the U.S. Food and Drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK1161","LABU","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642440872","title":"Shanghai Bao Pharma says US FDA clears IND for BJ007 subcutaneous infusion trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642440872","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642440872?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:27","pubTimestamp":1781087254,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals won US FDA clearance for an IND for subcutaneous infusion of BJ007, enabling the start of clinical trials.The study compares BJ007 subcutaneous infusion with IV ceftriaxone in healthy participants, focusing on pharmacokinetics and bioavailability.BJ007 is a subcutaneous ceftriaxone sodium candidate aimed at bacterial infections, targeting patients with difficult venous access.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL3HdRbQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642440848","title":"Shanghai Bao Pharmaceuticals Co - U.S. FDA Approves Ind for Subcutaneous Infusion of Bj007 for Injection on May 27, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642440848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642440848?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:27","pubTimestamp":1781087248,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nFWN42I0EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175689548","title":"Movement Alert｜Bao Pharmaceuticals-B Falls 5.19% in Regular Trading, Continued Low-Level Consolidation After Flash Crash Compounded by Biotech Sector Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=1175689548","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175689548?lang=en_us&edition=fundamental","pubTime":"2026-06-08 11:55","pubTimestamp":1780890919,"startTime":"0","endTime":"0","summary":"On June 8, Bao Pharmaceuticals-B declined 5.19% in regular trading, trading at 20.42 HKD/share, with trading volume of 16.43 million HKD. The stock continues to consolidate at depressed levels...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170212748","title":"BAO PHARMA-B's Groundbreaking Low-Immunogenic IgG Degrading Enzyme Ricefidase Reports Positive Phase II Results for Anti-GBM Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=1170212748","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170212748?lang=en_us&edition=fundamental","pubTime":"2026-06-06 10:42","pubTimestamp":1780713753,"startTime":"0","endTime":"0","summary":"Significant results from a Phase II clinical study for a novel treatment in anti-GBM disease were presented at the 63rd European Renal Association Congress. The study, led by a team from Peking...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185904720","title":"Movement Alert｜Bao Pharmaceuticals-B Rises 5.59% in Regular Trading, Core Pipeline KJ103 NDA Accepted by NMPA with Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1185904720","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185904720?lang=en_us&edition=fundamental","pubTime":"2026-06-05 09:42","pubTimestamp":1780623753,"startTime":"0","endTime":"0","summary":"On June 5, Bao Pharmaceuticals-B rose 5.59% in regular trading, trading at 24.22 HKD/share, with trading volume of 20.86 million HKD.On the news front, the company announced on June 4 that the new...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640152754","title":"Bao Pharmaceuticals' Application for Desensitization Therapy Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2640152754","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640152754?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:03","pubTimestamp":1780574615,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals'  new drug application for KJ103 for injection was accepted by China's National Medical Products Administration and granted priority review status, according to a Thursday Hong Kong bourse filing.The acceptance is for use of the drug for desensitization therapy in highly sensitized kidney transplant patients.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640159253","title":"BRIEF-Shanghai Bao Pharmaceuticals Says NMPA Accepts NDA For KJL03 For Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2640159253","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640159253?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:26","pubTimestamp":1780568796,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Bao Pharmaceuticals Says NMPA Accepts NDA For KJL03 For InjectionJune 4 (Reuters) - Shanghai Bao Pharmaceuticals Co Ltd 2659.HK:NMPA ACCEPTS NDA FOR KJ103 FOR INJECTION ON JUNE 4, 2026Further company coverage: 2659.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C013:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172297791","title":"BAO PHARMA-B gains NMPA priority review for first-in-class IgG-degrading enzyme KJ103 in kidney transplant desensitization","url":"https://stock-news.laohu8.com/highlight/detail?id=1172297791","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172297791?lang=en_us&edition=fundamental","pubTime":"2026-06-04 17:43","pubTimestamp":1780566213,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B, 02659) announced that China’s National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for KJ103 for Injection on...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139198524","title":"Baoji Pharmaceutical-B Receives NMPA Acceptance for New Drug Application of Injectable KJ103","url":"https://stock-news.laohu8.com/highlight/detail?id=1139198524","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139198524?lang=en_us&edition=fundamental","pubTime":"2026-06-04 17:30","pubTimestamp":1780565436,"startTime":"0","endTime":"0","summary":"Baoji Pharmaceutical-B (HKEX: 02659) announced that on June 4, 2026, the New Drug Application (NDA) for its self-developed injectable KJ103 was accepted for review by China's National Medical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IPOS","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155284","title":"Shanghai Bao Pharma says China NMPA accepts KJ103 injection NDA for kidney transplant desensitization therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155284","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640155284?lang=en_us&edition=fundamental","pubTime":"2026-06-04 17:26","pubTimestamp":1780565216,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals’ new drug application for KJ103 injection was accepted by China’s NMPA for desensitization in highly sensitized kidney transplant patients.The company said its Phase III data supported the filing, citing 100% desensitization success and 100% transplant success in the study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL84h8tb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155285","title":"Shanghai Bao Pharmaceuticals Co - Nmpa Accepts Nda for Kj103 for Injection on June 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640155285?lang=en_us&edition=fundamental","pubTime":"2026-06-04 17:26","pubTimestamp":1780565213,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C013:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154040634","title":"Movement Alert｜Baoji Pharma-B Rises 13.37% in Regular Trading, Oversold Rebound After Hitting 52-Week Low Amid Multiple Positive Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=1154040634","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154040634?lang=en_us&edition=fundamental","pubTime":"2026-06-04 13:12","pubTimestamp":1780549973,"startTime":"0","endTime":"0","summary":"On June 4, Baoji Pharma-B surged 13.37% in regular trading, trading at 24.12 HKD/share, with trading volume of 49.80 million HKD. The stock staged a strong rebound after two consecutive sessions of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122154316","title":"Movement Alert｜BaoPharma-B Falls 5.3% in Regular Trading, Biotech Sector Systematic Weakness Extends Selling Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1122154316","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122154316?lang=en_us&edition=fundamental","pubTime":"2026-06-02 15:53","pubTimestamp":1780386795,"startTime":"0","endTime":"0","summary":"On June 2, BaoPharma-B fell 5.3% in regular trading, trading at 21.96 HKD/share, with trading volume of approximately 39.55 million HKD. The decline was primarily driven by systematic weakness across...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":131,"code":"91000000","status":"200"}]}}